Press release
Modus Therapeutics announces positive topline data from its Phase 1b LPS provocation study evaluating the potential of sevuparin for treatment of sepsis
February 22, 2023Business Services
STOCKHOLM, SWEDEN – 21 February 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet …
Beckley Psytech receives FDA Investigational New Drug (IND) approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT (Mebufotenin)
February 21, 2023Business Services
Oxford, United Kingdom – 21 FEBRUARY 2023 – Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric …
AstraZeneca and MSD present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
February 20, 2023Business Services
Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer …
SMC recommends Opdivo® (nivolumab) for use post-surgery in specific urothelial cancer patients
February 20, 2023Business Services
(Uxbridge, Middlesex, 13 February 2023) – The Scottish Medicines Consortium (SMC) has accepted Bristol Myers Squibb’s (BMS’) nivolumab for the …
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic CastrationResistant Prostate Cance
February 20, 2023Business Services
BEERSE, BELGIUM, 16 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the …
UK pharma packaging giant Origin celebrates its 60th anniversary
February 13, 2023Business Services
13th FEBRUARY 2023, HULL, UK: Leading UK pharmaceutical packaging and solutions provider, Origin, is celebrating its 60th anniversary. Origin …
CYDAR MEDICAL RAISES $11.5M (£9.3M) IN SERIES A FUNDING ROUND
February 13, 2023Business Services
CAMBRIDGE, UNITED KINGDOM, 13 FEBRUARY 2023 – Cydar Medical (“Cydar” or “the Company”) a global, cloud-based surgical software company, announces …
The First Women in Leadership Network to Support Diversity, Equality and Inclusion across the Life Sciences Industry launched in Denmark
February 9, 2023Business Services
9 February 2023, Denmark: Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior …
Redx Provides Progress Update on RXC007 Clinical Programme
February 9, 2023Business Services
Alderley Park, UK, 9 February 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 9, 2023Business Services
Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), a pioneer …
Availability of Sanofi’s Nexviadyme®▼(avalglucosidase alfa) provides NHS with new treatment for Pompe disease
February 8, 2023Business Services
READING, ENGLAND – Wednesday 8th February 2023. Sanofi announced today that healthcare specialists and patients living with Pompe disease will …
Cell and Gene Therapy Catapult to play significant role in establishing one of the largest life sciences campuses in Europe
February 8, 2023Business Services
London, 8th February 2023: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in …
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 8, 2023Business Services
Ghent, Belgium – 08 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 7, 2023Business Services
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted …
Oxford Science Enterprises strengthens Life Sciences investment team with appointment of Sanne de Jongh as Partner
February 7, 2023Business Services
Oxford, UK: February 7, 2023 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
